293 related articles for article (PubMed ID: 33666240)
1. Vaccination hesitancy and the "myth" on mRNA-based vaccines in Italy in the COVID-19 era: Does urgency meet major safety criteria?
Chirumbolo S
J Med Virol; 2021 Jul; 93(7):4049-4053. PubMed ID: 33666240
[TBL] [Abstract][Full Text] [Related]
2. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines.
Moghimi SM
Mol Ther; 2021 Mar; 29(3):898-900. PubMed ID: 33571463
[No Abstract] [Full Text] [Related]
3. Nucleoside-modified messenger RNA COVID-19 vaccine platform.
Roncati L; Corsi L
J Med Virol; 2021 Jul; 93(7):4054-4057. PubMed ID: 33675239
[TBL] [Abstract][Full Text] [Related]
4. Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation.
Erdeljic Turk V
Clin Immunol; 2021 Jun; 227():108748. PubMed ID: 33932618
[TBL] [Abstract][Full Text] [Related]
5. Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience.
Kaplan B; Farzan S; Coscia G; Rosenthal DW; McInerney A; Jongco AM; Ponda P; Bonagura VR
Ann Allergy Asthma Immunol; 2022 Feb; 128(2):161-168.e1. PubMed ID: 34699968
[TBL] [Abstract][Full Text] [Related]
6. Biphasic anaphylaxis after first dose of messenger RNA coronavirus disease 2019 vaccine with positive polysorbate 80 skin testing result.
Pitlick MM; Park MA; Gonzalez-Estrada A; Chiarella SE
Ann Allergy Asthma Immunol; 2021 Oct; 127(4):498-499. PubMed ID: 34343674
[No Abstract] [Full Text] [Related]
7. An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination.
Kantarcioglu B; Iqbal O; Walenga JM; Lewis B; Lewis J; Carter CA; Singh M; Lievano F; Tafur A; Ramacciotti E; Gerotziafas GT; Jeske W; Fareed J
Clin Appl Thromb Hemost; 2021; 27():10760296211021498. PubMed ID: 34060379
[TBL] [Abstract][Full Text] [Related]
8. From trial to practice: incidence and severity of COVID-19 vaccine side effects in a medically at-risk and vaccine-hesitant community.
Joyce MC; Mountjoy NJ; Johnson JA; Newman JT; Bandy DL; Atalla NA; Singh A; McElroy D
BMC Public Health; 2022 Dec; 22(1):2351. PubMed ID: 36517842
[TBL] [Abstract][Full Text] [Related]
9. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines.
Risma KA; Edwards KM; Hummell DS; Little FF; Norton AE; Stallings A; Wood RA; Milner JD
J Allergy Clin Immunol; 2021 Jun; 147(6):2075-2082.e2. PubMed ID: 33857566
[TBL] [Abstract][Full Text] [Related]
10. [Allergic reactions to COVID-19 vaccines: evidence and practice-oriented approach].
Klimek L; Eckrich J; Hagemann J; Casper I; Huppertz J
Internist (Berl); 2021 Mar; 62(3):326-332. PubMed ID: 33580823
[TBL] [Abstract][Full Text] [Related]
11. Beliefs, barriers and hesitancy towards the COVID-19 vaccine among Bangladeshi residents: Findings from a cross-sectional study.
Hossain MS; Islam MS; Pardhan S; Banik R; Ahmed A; Islam MZ; Mahabub MS; Sikder MT
PLoS One; 2022; 17(8):e0269944. PubMed ID: 35998135
[TBL] [Abstract][Full Text] [Related]
12. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Shaw RH; Stuart A; Greenland M; Liu X; Nguyen Van-Tam JS; Snape MD;
Lancet; 2021 May; 397(10289):2043-2046. PubMed ID: 33991480
[No Abstract] [Full Text] [Related]
13. Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES
JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808
[TBL] [Abstract][Full Text] [Related]
14. Attitudes towards Anti-SARS-CoV2 Vaccination among Healthcare Workers: Results from a National Survey in Italy.
Di Gennaro F; Murri R; Segala FV; Cerruti L; Abdulle A; Saracino A; Bavaro DF; Fantoni M
Viruses; 2021 Feb; 13(3):. PubMed ID: 33652829
[TBL] [Abstract][Full Text] [Related]
15. Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older.
Simone A; Herald J; Chen A; Gulati N; Shen AY; Lewin B; Lee MS
JAMA Intern Med; 2021 Dec; 181(12):1668-1670. PubMed ID: 34605853
[TBL] [Abstract][Full Text] [Related]
16. Maintaining Safety with SARS-CoV-2 Vaccines.
Castells MC; Phillips EJ
N Engl J Med; 2021 Feb; 384(7):643-649. PubMed ID: 33378605
[No Abstract] [Full Text] [Related]
17. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
Greenberg RS; Ruddy JA; Boyarsky BJ; Werbel WA; Garonzik-Wang JM; Segev DL; Imus PH
BMC Cancer; 2021 Dec; 21(1):1354. PubMed ID: 34961488
[TBL] [Abstract][Full Text] [Related]
18. The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey.
Di Noia V; Renna D; Barberi V; Di Civita M; Riva F; Costantini G; Aquila ED; Russillo M; Bracco D; La Malfa AM; Giannarelli D; Cognetti F
Eur J Cancer; 2021 Aug; 153():260-264. PubMed ID: 34183225
[TBL] [Abstract][Full Text] [Related]
19. Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.
Wang M; Wen W; Zhou M; Wang C; Feng ZH
Am J Cardiol; 2022 Mar; 167():155-157. PubMed ID: 35063268
[No Abstract] [Full Text] [Related]
20. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
